Illumina, Inc. (NASDAQ:ILMN) Stake Boosted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,062.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 93,917 shares of the life sciences company’s stock after acquiring an additional 85,840 shares during the period. Los Angeles Capital Management LLC’s holdings in Illumina were worth $12,248,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Envestnet Portfolio Solutions Inc. boosted its holdings in Illumina by 426.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after purchasing an additional 12,521 shares in the last quarter. Jupiter Asset Management Ltd. bought a new stake in Illumina in the first quarter worth $4,527,000. US Bancorp DE boosted its holdings in Illumina by 33.9% in the first quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after purchasing an additional 8,001 shares in the last quarter. Cetera Advisors LLC bought a new stake in Illumina in the first quarter worth $610,000. Finally, Weybosset Research & Management LLC boosted its holdings in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after purchasing an additional 8,650 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Up 0.3 %

ILMN opened at $151.50 on Tuesday. The firm’s fifty day moving average is $138.09 and its two-hundred day moving average is $123.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43. The firm has a market cap of $24.03 billion, a PE ratio of -15.21 and a beta of 1.13. Illumina, Inc. has a twelve month low of $92.26 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the business posted $0.33 earnings per share. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. Barclays upped their price target on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Scotiabank decreased their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Canaccord Genuity Group upped their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Finally, HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $163.71.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.